A tumor suppressor gene, p53, controls cellular responses to a variety of stress conditions, including DNA damage and hypoxia, leading to growth arrest and/or apoptosis. Recently, we demonstrated that in blind subterranean mole rats, Spalax, a model organism for hypoxia tolerance, the p53 DNA-binding domain contains a specific Arg174Lys amino acid substitution. This substitution reduces the p53 effect on the transcription of apoptosis genes (apaf1, puma, pten and noxa) and enhances it on human cell cycle arrest and p53 stabilization/homeostasis genes (mdm2, pten, p21 and cycG). In the current study, we cloned Spalax apaf1 promoter and mdm2 intronic regions containing consensus p53-responsive elements. We compared the Spalax-responsive elements to those of human, mouse and rat and investigated the transcriptional activity of Spalax and human Arg174Lys-mutated p53 on target genes of both species. Spalax and human-mutated p53 lost induction of apaf1 transcription, and increased induction of mdm2 transcription. We conclude that Spalax evolved hypoxia-adaptive mechanisms, analogous to the alterations acquired by cancer cells during tumor development, with a bias against apoptosis while favoring cell arrest and DNA repair.
A tumor suppressor gene, p53, controls cellular responses to a variety of stress conditions, including DNA damage and hypoxia, leading to growth arrest and/or apoptosis. Recently, we demonstrated that in blind subterranean mole rats, Spalax, a model organism for hypoxia tolerance, the p53 DNA-binding domain contains a specific Arg174Lys amino acid substitution. This substitution reduces the p53 effect on the transcription of apoptosis genes (apaf1, puma, pten and noxa) and enhances it on human cell cycle arrest and p53 stabilization/homeostasis genes (mdm2, pten, p21 and cycG). In the current study, we cloned Spalax apaf1 promoter and mdm2 intronic regions containing consensus p53-responsive elements. We compared the Spalax-responsive elements to those of human, mouse and rat and investigated the transcriptional activity of Spalax and human Arg174Lys-mutated p53 on target genes of both species. Spalax and human-mutated p53 lost induction of apaf1 transcription, and increased induction of mdm2 transcription. We conclude that Spalax evolved hypoxia-adaptive mechanisms, analogous to the alterations acquired by cancer cells during tumor development, with a bias against apoptosis while favoring cell arrest and DNA repair. Oncogene (2007 Oncogene ( ) 26, 2507 Oncogene ( -2512 Oncogene ( . doi:10.1038 published online 16 October 2006 Keywords: subterranean mole rat; hypoxia; p53; apaf1; mdm2 P53, a central player in orchestrating cell responses to stress stimuli, is a major guard against cancer. Mutations that inactivate or mutilate p53 are the most common genetic alternations in human cancer. The p53 protein exerts its regulatory and tumor-suppressive activities mainly via its function as a transcription factor. Many of the p53-responsive genes mediate cellular response pathways, such as growth arrest and apoptosis (Levine, 1997; Vousden and Lu, 2002; Klein, 2004) as well as angiogenesis failure (Graeber et al., 1996; Kinzler and Vogelstein, 1996) . Because p53 is altered in many types of human cancer, manipulation of the p53 pathway is an essential event in carcinogenesis (Vogelstein and Kinzler, 2004) . Some parts of solid tumors suffer from hypoxia due to lack of adequate vascularization. Upregulation of wild-type p53 under hypoxic conditions results in apoptosis (Goda et al., 2003) . In human cancers, alteration of p53, in these hypoxic microenvironments, plays an important role in regulating the survival and angiogenic response of the tumor (Hollstein et al., 1991; Royds et al., 1998; Vousden and Lu, 2002) . Testing the role of hypoxia in the survival of established tumors is not easy as they are characterized by multiple genetic aberrations. However, this hypothesis can be tested evolutionarily in nonmalignant cells of organisms exposed to environmental hypoxia such as subterranean mammals.
Spalax as a mammalian model organism for hypoxia tolerance
Blind subterranean mole rats superspecies, Spalax ehrenbergi, live in sealed underground burrows under extreme hypoxic/hypercapnic conditions (Nevo, 1999; Nevo et al., 2001) . In laboratory conditions, Spalax survive in 3% O 2 and up to 15% CO 2 for approximately 11 h, whereas Rattus die after 2-4 h (Avivi et al., 1999) in the same conditions. In the field, Spalax adapt to abrupt and sharp fluctuations in O 2 and CO 2 levels. We recorded 7% O 2 and 6% CO 2 in the flooded burrows during the rainy season (Shams et al., 2005a) . Spalax evolved adaptive respiratory mechanisms to tolerate hypoxia (Nevo, 1999; Nevo et al., 2001) , including blood properties and blood vessel density (Widmer et al., 1997; Avivi et al., 1999) , and structural and functional changes in a growing list of genes. This includes the genes whose expression is mediated by hypoxia, such as vascular endothelial growth factor (VEGF), its transcriptionactivator hypoxia-inducible factor 1a and mRNA stabilizer HuR (Avivi et al., 1999 , as well as erythropoietin (Shams et al., 2004 and its receptor (Shams et al., 2005a) , hemoglobin, myoglobin, haptoglobin (Nevo, 1999) , neuroglobin and cytoglobin (unpublished).
Capillary growth, both developmentally (Peters et al., 1993) and in response to hypoxia (Shweiki et al., 1992) , has been demonstrated to depend critically on a few growth factors, a major one is the angiogenic factor VEGF. Our previous results (Avivi et al., 1999) indicated that Spalax VEGF expression is similar to its expression in cancer growths (Jubb et al., 2004; Kuramochi et al., 2006) , for example, it is constitutively expressed in maximal levels under normoxia with no further increase under hypoxia. This observation, in fact, triggered our interest in studying Spalax p53 in an effort to use this non-tumoral, hypoxia-adaptive model to study evolutionary changes in p53, analogous to acquired tumoral p53 mutations. Indeed, cloning of Spalax p53 (Ashur-Fabian et al., 2004; Avivi et al., 2005a) revealed two Spalax-specific substitutions in the p53 DNA-binding domain, exchanging arginines (R) for lysine (K) at codons corresponding to position 174 and 209 in humans. Both amino-acid changes are identical to known human tumor-associated mutations. Spalax p53's effect on the transcription of several human p53 target genes (Ashur-Fabian et al., 2004) indicated a gain of function on G1 arrest and p53 homeostasis target genes (mdm2, pten, cycG and p21) and loss of function on apoptotic genes (apaf1, puma, noxa and bax). Spalax's hypoxia-adaptive mechanisms, thus, may be analogous to the alterations acquired by cancer cells during tumor development.
In the current study, we further explored whether the same bias observed using human promoters would be seen when Spalax p53 target genes are used. For this purpose, we cloned the promoter of Spalax apaf1 and Spalax mdm2 intronic region containing p53-binding site and compared it to known human, mouse and rat promoters. Furthermore, we used reporter assays to examine Spalax p53 to transcriptional activation of its own target genes. In addition, BaF3 cells were transfected with human or Spalax p53, after which the apoptosis level was determined using fluorescenceactivated cell sorter (FACS) analysis.
P53-responsive elements are evolutionarily preserved between human, mouse, rat and Spalax Promoter sequence of apaf1 from Spalax judaei (2n ¼ 60) (Accession No. AM398155), equivalent to the human one used in this study (basepairs 217-1103; Accession No. NM_001160) was cloned by polymerase chain reaction (PCR) using oligonucleotides designed according to the published human (Accession No. NM_001160), rat (Accession No. NM_023979) and mouse (Accession No. AF064071) sequences. An intronic region of mdm2-containing p53 binding site and equivalent to the human one used in this study (base pairs 1220-2087, Accession No. MN_002392) was cloned by PCR from Spalax galili (2n ¼ 52) (Accession No. AM398156) using oligonucleotides designed according to the published human (Accession No. MN_002392) and mouse (Accession No. MN_0107869) sequences. The consensus-responsive elements to which p53 binds contain a set of two decamers of: RRRCWWGYYY (R-purines, Y-pyrimidines and W ¼ A or T), separated by 0-13 bp (el-Deiry et al., 1992) . The specific p53 consensus binding sites reside within the promoter and/or an intronic region of its target genes (Rozenfeld-Granot et al., 2002) . Multiple alignment analysis (accelrys DS gene 1.5 program, Accelrys Software Inc., San-Diego, CA, USA) revealed that the first decamers set in Spalax apaf1 promoter is highly preserved between the human, mouse and rat (highlighted in yellow; Figure 1a ). However, Spalax seems to lack two of the three purines in the last decamer, with a responsive element of only eight bases: RCWWGYYY. We believe, therefore, that only the first set in the Spalax apaf1 promoter is biologically active for human or Spalax p53 binding, whereas the second set probably does not play a role in the binding of p53. Spalax mdm2 p53's responsive elements show more similarity with both decamer sets, with only minor changes between species (highlighted in yellow; Figure 1b ). Overall, similarities across species for both p53 target genes are observed, suggesting evolutionary biological significance.
Spalax p53 displays loss of function on Spalax apaf1 activation and gain of function on Spalax mdm2
Recently, we investigated whether Spalax p53 activates the transcription of several human target genes (AshurFabian et al., 2004) . Reporter assays, on the one hand, uncovered that Spalax p53 protein is unable to induce apoptosis-regulating target genes, including apaf1, a central player in the mitochondrial apoptotic pathway described by our group and others (Kannan et al., 2001; Moroni et al., 2001; Rozenfeld-Granot et al., 2002) . On the other hand, cell cycle arrest and p53 stabilization/ homeostasis genes (such as mdm2) were overactivated by Spalax p53. In order to establish the results observed using human target genes, reporter assays with the twocloned Spalax p53 target genes were performed. In this work, transient transfection assays were performed on H1299 (p53-null) human cell lines, using Spalax or human p53 expression plasmids. Co-transfections were performed using luciferase construct containing human or Spalax apaf1 promoter and mdm2 intronic regions. The results, summarized with respect to wild-type human p53 (Figure 2 ), demonstrate that human p53-induced transcriptional activation of both human and Spalax target genes examined. However, Spalax p53 exhibits loss of function on human and Spalax apaf1 promoters (complete and 3.3-fold loss of function, respectively, Po0.01), while showing a gain-of-function activity on human and Spalax mdm2 (up to 1.6-and 2.5-fold, respectively, Po0.05). A mutated human p53 (H179R), used as a negative control, showed a partial or complete loss of function on all targets tested (data not shown). Concerning mdm2 expression activation, Spalax p53 exhibited a gain-of-function activity on both human and Spalax mdm2 intronic regions. The pattern of expression of both p53-target genes corroborates our previous results (Ashur-Fabian et al., 2004) .
To test the bias of Spalax p53 against apoptosis in vivo, a preliminary experiment was carried out. Interleukin (IL)-3-dependent BaF3 cells (Oliver et al., 1993) , at a density of 10 6 cells, were transiently transfected with either human wild-type p53 or Spalax p53. FACS analysis revealed that human p53 induced extensive apoptosis (44.174.8%) compared to mock-transfected cells (4.771.8%; Po0.01). In contrast, Spalax p53-induced apoptosis rate was 23.274.2%, significantly lower (Po0.05) than the apoptosis rate measured with human p53 (see representative of three independent experiments in Figure 3) . Furthermore, as can be seen from the example shown in Figure 3 , the percentage of cells that enter the G2 phase after induction with human p53 (8.1%) is significantly lower than that induced by Spalax p53. The latter was found to be a potent promoter of cell cycle arrest with a higher percentage of cells entering the G2 phase (27.3%).
'Spalax-specific' changes in the human p53 protein abrogates activity toward apaf1 and gain of function toward mdm2
Our previous work (Ashur-Fabian et al., 2004) established two Spalax-specific amino acid substitutions in the p53 DNA-binding domain, changing arginine (R) to lysine (K) in Spalax at positions corresponding to codons 174 and 209. Further comparison to an additional 41 different species and sub-species indicated that only codon 174 is highly conserved and thus may be of biological importance. Moreover, we recently illustrated, using 3D models, that the Lys174 in Spalax p53 protein is essential to the dimer formation, before DNA binding. To test whether the exchange of lysines for arginines in Spalax p53 protein is responsible for loss of activity of apaf1 promoter and the overactivation of mdm2, human p53 amino acids arginines (R) at positions 174 and/or 209 were changed to lysines (K). The different human p53 plasmids (wild type and 'Spalax mutated') were co-transfected with apaf1 and mdm2 promoter luciferase constructs of either human or Spalax. Whereas human p53-activated apaf1, the mutated human p53 R174K diminished the ability to activate both human and Spalax apaf1 targets (Figure 2 ). Substituting R209K in the human p53 plasmid had a slight or no effect when compared to the human wildtype p53. Alternation of both amino acids to the Spalaxspecific sequence resulted in a synergistic effect on apaf1 and an intermediate effect on mdm2 (Figure 2) . With regard to mdm2, substituting the R174K in the human p53 resulted in a gain-of-function mutation, with an overexpression of both human and Spalax mdm2 (1.3-to 1.6-fold respectively; Figure 2 ). However, p53 mutated at R209K and R174K þ R209K resulted in a partial loss of function. Hence, the current work reinforces the importance of Lys174 for the inactivation of apaf1 promoter versus a gain of function toward mdm2. Interestingly, a neighboring mutated V173L was also incapable of activating apaf1 promoter (Moroni et al., 2001) . Remarkably, the same Spalax p53 overactivated targets involved in cell cycle and p53 stabilization/ homeostasis, namely p21, cycG, pten and mdm2 (AshurFabian et al., 2004) . Similar results were obtained with 143A, 175P and 181L human p53 mutants, retaining the ability to trans-activate cell cycle arrest genes while failing to activate apoptotic target genes (Gagnebin et al., 1998) . Furthermore, several mutations from arginine to leucine at codon 175 (Klein et al., 2001) , isoleucine or serine (Ryan and Vousden, 1998) ablate apoptosis activity, but function as wild types in regard to cell cycle arrest, similar to the amino acid adaptation observed in Spalax p53. In a mouse model (Liu et al., 2004) in which p53 R175P mutation was introduced, the initiation of apoptosis was abrogated, whereas cell cycle arrest remained intact. Finally, although apaf1 and mdm2 genes display a high degree of conservation between Spalax and other species, and the effect of Spalax p53 on both human and Spalax target genes is similar, it cannot be ruled out that the altered activity
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A Avivi et al observed in Spalax may be due, in part, to Spalaxunique entities that are not present in other species.
Conclusions
p53 exerts its transcriptional activity by binding to specific consensus binding sites within the promoter and/or an intronic region of its target genes. The crosssimilarities observed in these target genes between species suggest evolutionary biological significance. We propose that sequence-specific changes in the Spalax p53 gene provide an example of how transcription factors that regulate many genes can also account for rapid and broad phenotypic diversity by altering the binding affinity to individual target genes. p53, through the creation of multiple phenotypes, controls the expression of multiple target genes (Resnick and Inga, 2003) . We believe that spalacids, as their origin is estimated some 40 million years ago (Nevo, 1999) , evolved hypoxiaadaptive mechanisms in many genes including p53. The Spalax p53 amino acid substitutions are in analogous sites to genetic and epigenetic alterations acquired by cancer cells. A single amino acid change observed in the Spalax p53 could have diverse effects on the ability to induce the transcription of different target genes, including the bias observed against apoptosis and for cell cycle and p53 stabilization/homeostasis target genes. This is a uniquely interesting case demonstrating how natural selection through hypoxia stress directs adaptive evolution of a transcription factor affecting higher fitness and survival of a wild mammal underground.
